Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Kodiak Sciences Inc. (KOD) Prices 5.19M Share Common Offering at $108/Sh
November 18, 2020 5:49 AM ESTKodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00... More
UPDATE: Morgan Stanley Downgrades Kodiak Sciences Inc. (KOD) to Equalweight
November 16, 2020 3:21 AM EST(Updated - November 16, 2020 5:47 AM EST)
(updating comment)
Morgan Stanley analyst Matthew Harrison downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Overweight to Equalweight with a price target of $125.00.
The analyst comments "We remain bullish on KSI-301's durability profile,... More
UPDATE: Goldman Sachs Downgrades Kodiak Sciences Inc. (KOD) to Neutral
November 13, 2020 4:41 AM EST(Updated - November 13, 2020 6:01 AM EST)
(updating comment)
Goldman Sachs analyst Graig Suvannavejh downgraded Kodiak Sciences Inc. (NASDAQ: KOD) from Buy to Neutral with a price target of $105.00.
The analyst comments "We raise our 12 month price target on Kodiak Sciences (KOD) to... More
Kodiak Sciences Inc. (KOD) PT Raised to $145 at BMO Capital
November 12, 2020 10:45 AM ESTBMO Capital analyst Matthew Luchini raised the price target on Kodiak Sciences Inc. (NASDAQ: KOD) to $145.00 while maintaining an Outperform rating.
The analyst commented, "We are raising our target price to $145 on higher probability of success (67% vs. 45%) and peak US wAMD share (20% vs. 17%). Our... More
